KIT N822K

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia4
KIT N822K	Imatinib Mesylate	Predictive	D	Supports Sensitivity Response	3	submitted	EID6958 Finally, although reports suggested and our study confirmed that D816 mutations were resistant to Gleevec (26), our results clearly show that t(8;21) leukemic cells carrying N822K mC-KIT, the most fre… (full text at CIViC) PMID 15650049 · Wang et al., 2005 · Open in CIViC	civic
KIT N822K	Ponatinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID7379 In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at I… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Acute Myeloid Leukemia4

KIT N822K

Imatinib Mesylate

Predictive

Supports Sensitivity Response

submitted

EID6958

Finally, although reports suggested and our study confirmed that D816 mutations were resistant to Gleevec (26), our results clearly show that t(8;21) leukemic cells carrying N822K mC-KIT, the most fre… (full text at CIViC)

PMID 15650049 · Wang et al., 2005 · Open in CIViC

civic

KIT N822K

Ponatinib

Predictive

Supports Sensitivity Response

accepted

EID7379

In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at I… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375931	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Gastrointestinal stromal tumor; Hereditary cancer-predisposing syndrome	germline	3	Jan 30, 2026	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

375931

Conflicting classifications of pathogenicity

criteria provided, conflicting classifications

Gastrointestinal stromal tumor; Hereditary cancer-predisposing syndrome

germline

Jan 30, 2026

clinvar

Gastrointestinal Stromal Tumor8
KIT N822K	Imatinib	Predictive	C	Supports Resistance	3	accepted	EID2918 147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC) PMID 16954519 · Heinrich et al., 2006 · Open in CIViC	civic
KIT N822K	Ponatinib	Predictive	D	Does Not Support Resistance	3	accepted	EID4167 A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secon… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT N822K	Ponatinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7408 Ponatinib possesses potent activity against N882K KIT mutant in preclinical experiments. PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT N822K	Regorafenib Anhydrous	Predictive	C	Supports Sensitivity Response	2	accepted	EID4595 This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC	civic
KIT N822K	Sunitinib	Predictive	D	Supports Resistance	—	submitted	EID4166 In an in vitro study, a 32D cell line expressing KIT N822K mutation (overexpression) demonstrated reduced sensitivity to sunitinib treatment (IC50: 37.0nM) compared to 32D cells expressing wild-type K… (full text at CIViC) PMID 24205792 · Zhao et al., 2014 · Open in CIViC	civic
KIT N822K	Sunitinib	Predictive	D	Supports Resistance	—	submitted	EID4168 In an in vitro study, a 32D cell line expressing KIT N822K mutation (overexpression) demonstrated reduced sensitivity to sunitinib treatment (IC50: 37.0nM) compared to 32D cells expressing wild-type K… (full text at CIViC) PMID 24205792 · Zhao et al., 2014 · Open in CIViC	civic
KIT W557_K558del AND KIT N822K	Regorafenib Anhydrous	Predictive	D	Supports Resistance	3	accepted	EID4169 In a set of preclinical experiments associated with gastrointestinal stromal tumor, the effects of the tyrosine kinase inhibitor regorafenib on Ba/F3 cell lines harboring the primary regorafenib-sensi… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT W557_K558del AND KIT N822K	Imatinib + SunitinibSubstitutes	Predictive	D	Supports Resistance	4	accepted	EID7414 Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with primary TKI-sensitizing del 557-558 mutation, which induced IL-3 independent growth… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic

Gastrointestinal Stromal Tumor8

KIT N822K

Imatinib

Predictive

Supports Resistance

accepted

EID2918

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic

KIT N822K

Ponatinib

Predictive

Does Not Support Resistance

accepted

EID4167

A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secon… (full text at CIViC)

PMID 25239608 · Garner et al., 2014 · Open in CIViC

civic

KIT N822K

Ponatinib

Predictive

Supports Sensitivity Response

submitted

EID7408

Ponatinib possesses potent activity against N882K KIT mutant in preclinical experiments.

PMID 25239608 · Garner et al., 2014 · Open in CIViC

civic

KIT N822K

Regorafenib Anhydrous

Predictive

Supports Sensitivity Response

accepted

EID4595

This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC)

PMID 22614970 · George et al., 2012 · Open in CIViC

civic

KIT N822K

Sunitinib

Predictive

Supports Resistance

—

submitted

EID4166

In an in vitro study, a 32D cell line expressing KIT N822K mutation (overexpression) demonstrated reduced sensitivity to sunitinib treatment (IC50: 37.0nM) compared to 32D cells expressing wild-type K… (full text at CIViC)

PMID 24205792 · Zhao et al., 2014 · Open in CIViC

civic

KIT N822K

Sunitinib

Predictive

Supports Resistance

—

submitted

EID4168

PMID 24205792 · Zhao et al., 2014 · Open in CIViC

civic

KIT W557_K558del AND KIT N822K

Regorafenib Anhydrous

Predictive

Supports Resistance

accepted

EID4169

In a set of preclinical experiments associated with gastrointestinal stromal tumor, the effects of the tyrosine kinase inhibitor regorafenib on Ba/F3 cell lines harboring the primary regorafenib-sensi… (full text at CIViC)

PMID 25239608 · Garner et al., 2014 · Open in CIViC

civic

KIT W557_K558del AND KIT N822K

Imatinib + SunitinibSubstitutes

Predictive

Supports Resistance

accepted

EID7414

Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with primary TKI-sensitizing del 557-558 mutation, which induced IL-3 independent growth… (full text at CIViC)

PMID 25239608 · Garner et al., 2014 · Open in CIViC

civic

Malignant Neoplasm1
KIT N822K	Imatinib	Predictive	D	Does Not Support Sensitivity Response	2	accepted	EID2448 In an in vitro study of imatinib sensitivity, KIT N822K was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid… (full text at CIViC) PMID 14645423 · Heinrich et al., 2003 · Open in CIViC	civic

Malignant Neoplasm1

KIT N822K

Imatinib

Predictive

Does Not Support Sensitivity Response

accepted

EID2448

In an in vitro study of imatinib sensitivity, KIT N822K was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid… (full text at CIViC)

PMID 14645423 · Heinrich et al., 2003 · Open in CIViC

civic

Evidence by cancer (13 items)

Clinical significance (1)